Sarepta Therapeutics, Inc.'s SEC filings document an operating biopharmaceutical company with common stock listed on the Nasdaq Global Select Market under SRPT. Form 8-K reports furnish quarterly and annual financial results, product revenue disclosures for ELEVIDYS and PMO therapies, and clinical or regulatory updates for Duchenne muscular dystrophy treatments and siRNA pipeline programs.
Other filings cover proxy governance, executive compensation, equity-award plans and leadership-transition disclosures. Material-event reports also describe capital-structure actions, including exchange agreements for convertible senior notes, issuance of new convertible notes, common stock consideration and related indenture terms.
Vanguard Portfolio Management LLC, on behalf of certain affiliated entities and accounts, reports updated passive ownership of Sarepta Therapeutics Inc. common stock on an amended Schedule 13G. As of June 30, 2026, Vanguard Portfolio Management is deemed to beneficially own 8,499,421 shares of Sarepta common stock, representing 8.05% of the class.
The filer has sole voting power over 121,951 shares and sole dispositive power over 8,499,421 shares, with no shared voting or dispositive power. The position includes shares held by Vanguard funds and other managed accounts for which Vanguard Portfolio Management or certain affiliates exercise voting and/or dispositive authority. Dividends and sale proceeds are attributable to those funds and clients, and no other single person has an interest in more than 5% of the class through these holdings.
BlackRock, Inc. reports significant ownership in Sarepta Therapeutics Inc common stock under an amended Schedule 13G. BlackRock and certain of its reporting business units beneficially own 16,642,620 shares of Sarepta common stock, representing 15.8% of the outstanding class as of the reporting date.
BlackRock has sole voting power over 16,353,161 shares and sole dispositive power over 16,642,620 shares, with no shared voting or dispositive power reported. The filing notes that one holder, iShares Core S&P Small-Cap ETF, has an interest in more than five percent of Sarepta’s outstanding common stock. The disclosure reflects only securities held by specified BlackRock business units, excluding those disaggregated under SEC Release No. 34-39538.
Sarepta Therapeutics, Inc. reported that Chief Executive Officer Michael Severino received significant equity awards on 2026-07-28. He was granted 2,224,342 stock options with a $17.74 exercise price, expiring 2036-07-28; 25% vests on 2027-07-28 and the remainder vests monthly over four years. He also received 756,104 restricted stock units, each for one share of common stock, vesting in substantially equal annual installments over four years, bringing his reported direct holdings to 2,224,342 options and 756,104 shares.
Sarepta Therapeutics, Inc. reported insider information for Michael Severino, who is identified as both a director and the company’s Chief Executive Officer. This Form 3 report lists no equity transactions or holdings, serving only to establish his status as a reporting insider.
Sarepta Therapeutics appointed Michael Severino, M.D. as Chief Executive Officer effective July 28, 2026, and as a Class I director serving until the 2028 annual meeting. He succeeds Douglas Ingram, who will step down as CEO and director on that date and remain as a consultant through December 31, 2026.
Under an employment agreement dated July 24, 2026, Dr. Severino receives an annual base salary of $1,180,000 and is eligible for a target bonus equal to 110% of base salary, with his 2026 bonus paid at 100% of target and prorated. He will receive a $35,000,000 sign-on equity package combining restricted stock units and premium priced stock options, with multi‑year vesting schedules. For a qualifying termination, he is entitled to salary continuation, bonus-related payments, COBRA premium support, outplacement services up to $20,000, and specified equity acceleration, with enhanced cash and full equity acceleration if the termination occurs within the defined change of control period. Mr. Ingram will be paid $15,000 per month under his consulting agreement.
Boor Kathryn Jean reported acquisition or exercise transactions in this Form 4 filing.
Sarepta Therapeutics, Inc. director Kathryn Jean Boor received an equity grant in the form of restricted stock units. She was granted 16,875 RSUs, each representing one share of common stock, at no cash cost. The RSUs vest on the earlier of the one-year anniversary of the grant date or the next annual meeting of stockholders that is at least 50 weeks after the prior year's meeting. Following this grant, she directly holds 25,138 shares of common stock.
Mayo Stephen reported acquisition or exercise transactions in this Form 4 filing.
Sarepta Therapeutics director Stephen Mayo received an equity grant in the form of restricted stock units. He was awarded 16,875 RSUs of common stock at no purchase price. Each RSU represents one share of common stock.
The RSUs will vest on the earlier of the one-year anniversary of the grant date and the next annual meeting of stockholders that occurs at least 50 weeks after the prior year’s annual meeting. Following this award, Mayo directly holds 18,640 shares of Sarepta common stock.
Wigzell Hans Lennart Rudolf reported acquisition or exercise transactions in this Form 4 filing.
Sarepta Therapeutics director Hans Lennart Rudolf Wigzell reported a stock-based compensation grant. He was awarded 16,875 restricted stock units (RSUs), each representing one share of Sarepta common stock at no cash cost. The RSUs will vest on the earlier of the one-year anniversary of the grant date or the next annual meeting of stockholders that occurs at least 50 weeks after the prior year’s annual meeting. Following this award, Wigzell directly holds 42,098 shares of Sarepta common stock. This represents a routine equity compensation grant rather than an open-market share purchase.
BEHRENS M KATHLEEN reported acquisition or exercise transactions in this Form 4 filing.
Sarepta Therapeutics director Kathleen M. Behrens reported a compensation-related equity grant rather than an open-market trade. She was awarded 16,875 restricted stock units (RSUs), each representing the right to receive one share of common stock at no cost. According to the terms, these RSUs will vest on the earlier of the one-year anniversary of the grant date or the next annual meeting of stockholders that occurs at least 50 weeks after the prior year’s annual meeting. Following this grant, she holds 214,357 shares of common stock directly, and a separate filing entry shows 10,000 shares of common stock held indirectly by a trust as a reported holding.
Sarepta Therapeutics, Inc. reported that director Deirdre P. Connelly acquired 16,875 shares of common stock through a grant of restricted stock units (RSUs) at $0.00 per share as director compensation. Following this award, she directly holds 22,100 shares of Sarepta common stock.
The footnote explains that each RSU represents one share of common stock and will vest on the earlier of the one-year anniversary of the grant date or the next annual stockholder meeting that occurs at least 50 weeks after the prior year’s meeting. This is a stock-based compensation grant rather than an open-market purchase.